Allarity strengthens DRP strategy with new patents and lab capabilities
Allarity received recent patent awards and CLIA certification to retain exclusive control of its Drug Response Predictor test for stenoparib, aiding its clinical development strategy.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed